Opko Health Inc (OPK)

[nbm16yankees]

Breaking News Instant updates and real-time market news.
OPK, PFE 15:13 04/29/20
Piper backs Overweight on Opko as BioReference starts COVID-19 antibody testing
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $3 price target on Opko Health (OPK) after it said its BioReference Laboratories will start offering SARS-CoV-2 antibody tests. Tenthoff noted that, importantly, Opko and partner Pfizer (PFE) will present Phase III somotrogon data on June 8 at ENDO Online 2020, and submit regulatory filings in the second half of the year. The analyst added that he does not yet know the impact of SARS-CoV-2 testing on BioReference's performance.
OPK PFE



OPK
PFE

OPK Opko Health

$2.32 /
+0.16 (+7.42%)

03/25/20 Piper Sandler
Piper Sandler sees FY20 U.S. sales of Opko's Rayaldee at $52.5M

03/13/20 Piper Sandler
Opko Health coronavirus tests in NY could drive upside, says Piper Sandler

03/10/20 Piper Sandler
Opko Health price target raised to $3.00 from $2.50 at Piper Sandler

03/06/20 Piper Sandler
Coronavirus test could boost Opko services revenue, says Piper Sandler